Profile data is unavailable for this security.
About the company
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
- Revenue in USD (TTM)0.00
- Net income in USD-50.75m
- Incorporated2018
- Employees17.00
- LocationClimb Bio Inc20 WILLIAM STREET, SUITE 145WELLESLEY HILLS 02481United StatesUSA
- Phone+1 (425) 276-2300
- Fax+1 (302) 636-5454
- Websitehttps://climbbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rezolute Inc | 0.00 | -77.18m | 336.60m | 71.00 | -- | 2.25 | -- | -- | -0.9291 | -0.9291 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -54.73 | -47.11 | -58.50 | -49.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.70 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -52.90m | 337.15m | 28.00 | -- | 1.90 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 338.29m | 56.00 | -- | 1.07 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 349.90m | 106.00 | -- | 2.22 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 351.72m | 299.00 | -- | 1.12 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 356.09m | 123.00 | -- | 44.95 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 356.48m | 4.00 | -- | 162.44 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -50.75m | 359.33m | 17.00 | -- | 2.03 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 212.07m | -84.20m | 361.67m | 368.00 | -- | 0.7761 | -- | 1.71 | -1.43 | -1.43 | 3.61 | 7.89 | 0.3403 | 6.46 | 4.55 | 576,288.10 | -13.51 | 1.56 | -16.20 | 1.80 | 94.44 | 91.45 | -39.70 | 3.99 | 3.10 | -- | 0.011 | 0.00 | 3.18 | -2.64 | -853.29 | -- | -13.62 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 363.27m | 34.00 | -- | 2.87 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 363.90m | 156.00 | -- | 1.72 | -- | 129.27 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 364.04m | 64.00 | -- | 3.03 | -- | 23.13 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 364.06m | 226.00 | -- | 1.15 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 367.19m | 25.00 | -- | -- | -- | 391.88 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 371.81m | 305.00 | -- | 0.6006 | -- | 13.12 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 373.54m | 32.00 | -- | 1.44 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
Data as of Feb 13 2026. Currency figures normalised to Climb Bio Inc's reporting currency: US Dollar USD
37.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 05 Jan 2026 | 17.96m | 26.34% |
| Affinity Asset Advisors LLCas of 30 Sep 2025 | 1.30m | 1.91% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.17m | 1.72% |
| Kynam Capital Management LPas of 30 Sep 2025 | 1.03m | 1.51% |
| Tang Capital Management LLCas of 30 Sep 2025 | 1.00m | 1.47% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 694.98k | 1.02% |
| Peapod Lane Capital LLCas of 31 Dec 2025 | 565.99k | 0.83% |
| Cantor Fitzgerald & Co.as of 30 Sep 2025 | 547.17k | 0.80% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 537.10k | 0.79% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 526.92k | 0.77% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
